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,~ummarv 
Clonidine-induced changes in the serotonergic neuronal activity of the central nervous system 
were estimated by measuring the concentrations of serotonin (5-HT) and its major metabolite, 
5-hydroxyindole-3-aeetic acid (5-HIAA), in the cerebrospinal fluid (CSF) of anesthetized rats. 
Clonidine (30 and 300 I.tg/kg, i.v.) led to 74% and 60% reductions in the concentration of 5-HT 
in the CSF 60 min after administration. CSF 5-H1AA concentrations were also decreased to 
77% and 66%, respectively. Clonidine-induced (30 ~tg/kg, i.v.) decreases in CSF 5-HT and 5- 
HIAA concentrations were attenuated by pretreatment with idazoxan (5 mg/kg, i.p.). Idazoxan 
by itself did not alter the CSF 5-HT and 5-HIAA concentrations. Decreased CSF 5-HT and 5- 
HIAA concentrations after i.v. administration of clonidine (30 ~tg/kg) were abolished by 
noradrenergic denervation after pretreatment with 6-hydroxydopamine (200 I.tg/rat, i.c.v.). These 
results suggest the possibility that clonidine acts to inhibit the serotonergic neuronal activity, 
which is mediated via the ~-adrenoceptors. It indicates, moreover, that noradrenergic nervous 
systems are involved in the clonidine-induced inhibition of serotonergic neuronal activity. 
Therefore, noradrenergic neurons play a significant role in mediating the actions of clonidine on 
serotonergic neuronal activity in the rat brain. 
Anatomical studies indicate that numerous brain regions receive both serotonergic and noradrenergic 
projections mainly from the raphe nucleus (1) and the locus coeruleus (2), respectively. The presence of both 
serotonergic and noradrenergic neurons in the same brain area suggests that a functional interaction exists between 
the two neuronal systems. Thus, the activity of serotonergic neurons, as reflected by serotonin (5-HT) turnover, 
might be modulated by noradrenergic nervous systems or, conversely, the activity of noradrenergic neurons might 
be regulated by serotonergic nervous systems. It is well known that clonidine, an cx2-adrenoceptor agonist, acts 
either directly at noradrenergic neuronal cell bodies to inhibit neuronal activity in areas of the brain such as the 
locus coeruleus (3, 4) or at presynaptic autoregulatory receptors to inhibit neurotransmitter release (5-7). 
Biochemical studies have provided evidence that clonidine also affects serotonergic neuronal function. Reinhard 
and Robert (8) reported that clonidine decreased the accumulation of 5-hydroxytryptophan (5-HTP), the serotonin 
(5-HT) precursor, and reduced the content of 5-hydroxyindole-3-acetic acid (5-HIAA), the major metabolite of 5- 
HT, in the rat cerebral cortex. Geyer and Lee (9) found that clonidine inhibited 5-HT turnover in the rat dorsal 
raphe nuclus and striatum. In contrast, Maj et al. (10) reported that clonidine increased the 5-HT content of the rat 
whole brain. Clement et al. (11) showed that high dose of clonidine increased extraneuronal 5-HIAA levels in the 
rat nucleus raphe dorsalis, whereas low dose of clonidine decreased them. Thus, whether clonidine modulates the 
serotonergic nervous system remains to be ascertained. 
In an attempt to estimate serotonergic or noradrenergic neuronal activity, mordern neurochemical methods 
such as in vivo microdialysis, in vivo voltammetry, push-pull cannulation and sampling of cerebrospinal fluid 
(CSF) have been applied to measure extracellular levels of 5-HT or noradrenaline (NA) in various brain regions. 
Among these approaches, CSF determination of 5-HT (or NA) concentrations is advantageous for assessment of 
the global neuronal activity in the central nervous systems. Since this method enables repeated sampling without 
tissue destruction, it would be a useful methods, were if available clinically, for the assessment of central 
serotonergic or noradrenergic neuronal activity. Some investigators have measured CSF NA concentrations to 
evaluate pharmacologically noradrenergic neuronal activity. For instance, CSF NA concentrations in humans (12) 
and animals (13) decreased following administration of an ~t2-adrenoceptor agonist, e.g., clonidine and xylazine, 
respectively. Few reports are available, however, on the measurement of CSF 5-HT concentrations following drug 
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administration due to the difficulty of analytical techniques. Moreover, Anderson et al. (14) have recently pointed 
out that the clinical utility of human CSF 5-HT determination is in question because of its extremely low levels. 
Therfore, the pharmacological significance of CSF 5-HT concentrations has not been established. 
Recently, we have developed a technique of combinig high-performance liquid chromatography (FIPLC) 
with electrochemical detection (ECD) that enables the simultaneous measurement of  5-HT and 5-HIAA 
concentrations in small amounts of rat CSF (15). With this method, we have demonstrated that CSF 5-HT levels 
provide a direct indication of central serotonergic neuronal activity (16). The present study was undertaken to 
evaluate the pharmacological significance of  CSF 5-HT concentrations. For this purpose, the modulation of 
serotonergic neuronal activity by clonidine was investigated through the determination of CSF 5-HT and 5-HIAA 
concentrations using HPLC-ECD. Focus was placed on the following points : 1) the effect of intravenous 
administration of clonidine on CSF 5-HT and 5-HIAA concentrations in anesthetized rats; and 2) the effect of 
selective ot2-adrenoceptor antagonist, idazoxan, on clonidine-induced changes in CSF 5-HT and 5-HIAA 
concentrations. Furthermore, in order to investigate whether the pharmacological effects of clonidine on 
serotonergic neurons involve noradrenergic mechanisms, experiments were performed on rats that were chemically 
denervated by pretreatement with catecholamine neurotoxin, 6-hydroxydopamine (6-OHDA). 
M e t h o d s  
Generals: Male Wistar rats from 15 to 20 weeks of age weighing 250 to 350 g were anesthetized by the 
intraperitoneally (i.p.) injection of ct-chloralose, 50 mg/kg, and urethane, 500 mg/kg. A polyethylene cannula 
(2.5 cm × 0.6 mm, I.D.) was inserted into the cisterna magna via the atlanto-occipital membrane under a Wild 
M650 stereoscopic dissecting microscope. Thirty minutes after cannulation, CSF was allowed to flow by gravity 
from the cisterna magna via a microhematocrit tube (7.5 cm × 1.5 mm, I.D.) into iced vials. The CSF sampling 
flow rate was approximately 20 I.tl/min. Although a sampling volume of 5 I-tl was sufficient to determine CSF 5- 
HIAA concentrations, a volume of 40-50 lal was nessasary for simultaneous determination of both 5-HIAA and 5- 
HT from the same sample because of the extremely low concentration of 5-HT in the CSF. The total CSF 
sampling volume never exceeded 150 ~tl for any rat. Each fraction was examined cytologically for contamination 
with blood. Intravenous administration (i.v.) of clonidine (3, 30 and 300 tag/kg) or saline (0.5 ml/kg) was 
performed via a cannula inserted into the femoral vein. Idazoxan (5 mg/kg, i.p.) was injected 10 min before i.v. 
administration of clonidine (30 tag/kg). Blood pressure and heart rate were monitored continuously via the femoral 
artery with a pressure transducer (Nihon Kohden, Tokyo, Japan). Rectal temperature was maintained between 37 
and 38°C with a heating pad. In order to chemically denervate the noradrenergic neurons, rats were anesthetized 
with ketamine (100 mg/kg, i.p), and 6-OHDA (200 ~g/rat) was injected intracerebroventricularly (i.c.v.) using a 
stereotaxic apparatus. The rats in these experiments were injected with pargyline (25 mg/kg, i.p) 10 min before 
the administration of 6-OHDA. Effects of clonidine upon CSF 5-HT and 5-HIAA concentrations were determined 
14 days after the i.c.v, injection of neurotoxin. 
Analysis: Fourty - 50 ~1 of unprocessed CSF was injected directly into the HPLC within a few minutes 
following the sampling. 5-HT and 5-HIAA were measured by ECD as described previously (16). As an index of 
noradrenergic neuronal activity (17), the CSF concentration of 3,4-dihydroxypehynlacetic acid (DOPAC) was 
determined simultaneously with 5-HT and 5-HIAA. The HPLC-ECD system consisted of a pump (EP-10) 
coupled to a reversed phase column (MA-5ODS, ODS, 5 ktm particle size) and an electrochemical detector (ECD- 
100). All equipment was purchased from Eicom, Co., Ltd (Kyoto, Japan). The mobile phase consisted of citric 
acid-sodium acetate buffer (pH 3.5), 10 I.tM EDTA-2Na and 230 mg/1 1-ocmnesulfonate. 15-18% (V/V) methanol 
was added to this solution depending on the column conditions. 
Drugs: Clonidine hydrochloride (Sigma Chemical Co., St.Louis, MO. USA), idazoxan hydrochloride (Reckitt and 
Colman, Jull, UK), 6-OHDA hydrochloride (Sigma) and pargyline hydrochloride (Sigma) were used. 
Statistics: Statistical comparisons were carried out using analysis of variance followed by Student's t-test. Values 
o fp  less than 5% were considered significant. All results were expressed as mean _+ SEM. 
R e s u l t s  
CSF 5-HT concentrations: Basal levels of CSF 5-HT, measured 30 min after eannulation and immediately before 
administration of clonidine (3, 30 or 300 ~tg/kg, i.v), did not differ significantly from the levels of saline-treated 
control rats. The CSF 5-HT concentrations were increased 60 min after treatment of rats with saline (15.8 + 9.5% 
increase, n.s.). There was no further change in the CSF 5-HT concentrations 120 min after saline administration. 
In contrast, clonidine decreased the CSF 5-HT concentrations dose-dependently. Sixty minutes after 
administration, clonidine (30 lag&g, i.v) caused a significant 26.2 _+ 13.0% decrease in CSF 5-HT from basal 
levels and a significant 42.0% decrease in CSF 5-HT from levels measured in saline-treated animals at the same 
point in time. There was no further change in the CSF 5-HT concentrations 120 min after administration of 
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clonidine. Clonidine (300 pg/kg, i.v.) significantly caused a decrease in CSF 5-HT concentrations from either 
basal levels or those measured in saline-treated animals at the same point in time (Table I). 
TABLE I 
Effects  of  Clonidine on Ccrebrospinal Fluid (CSF) 5-HT Concentrat ions (pg/ml). 
G r o u p s  (n) 0min 60min %Chan[~e 120rain %Chan~e 
C o n t r o l  (6) 384.98 450.02 15.83 447.91 15.99 
_+82.01 _+113.35 _+9.50 _+102.35 _+8.89 
C l o n i d i n e  (4) 306.42 228.57 -17.82 2 I I . 5 2  -15.88 
(3 ~tg/kg, i.v.) _+60.43 _+61.49 _+21.94 _+36.31 _+35.85 
C l o n i d i n e  (5) 466.92 326.10 26.15" 341.55 -25.52* 
(30 ~tg/kg, i.v.) _+120.12 _+80.35 _+12.96 _+108.43 _+14.43 
C l o n i d i n e  (6) 344.98 192.58 -39.89** 191.09 -51.19"* 
(300 rtg/kg, i.v.) _+137.63 _+74.73 _+12.76 _+72.89 -+14.68 
l d a z o x a n  (5) 319.53 277.25 9.44 307.77 -8.76 
(5 mg/kg, i.p.) _+107.08 _+35.54 -+22.30 -+113.45 _+9.63 
Idazoxan(5 mg/kg,i.p.) (5) 307.93 258.90 -5.22 234.81 -16.54 
+ C l o n  id ine  80.13 -+49.05 _+17.53 _+45.72 _+12.26 
(30 p.g/kg, i.v.) 
6-OHDA(200 R-g,i.c.v.) (5) 342.88 423.69 54.35 350.46 22.97 
+ C l o n i d i n e  _+50.88 _+90.59 _+78.06 _+12.47 _+27.33 
(30 ~/k~, i.v.) 
Data presented are mean _+ SEM. * p<0.05 and ** p<0.01 compared to controls. 
CSF 5-HIAA concentrations: Basal levels of CSF 5-HIAA measured before administration of  either saline or 
clonidine (3, 30 or 300 l-tg/kg, i.v) did not differ significantly from the levels of  normal rats. The CSF 5-HIAA 
concentrations were not significantly changed 60 min and 120 min after treatment with saline. Clonidine, 3 
pg/kg, i.v., did not affect the CSF 5-HIAA concentrations, while 30 and 300 pg/kg, i.v. decreased significantly 
the CSF 5-HIAA concentrations. Sixty minutes after administration, clonidine, 30 I-tg/kg, i.v., caused a 23.1 + 
4.3% decrease in CSF 5-HIAA from basal levels and a 31.0% decrease in CSF 5-HIAA concentration from levels 
measured in saline-treated animals at the same point in time. There was no further change in the CSF 5-HIAA 
concentrations 120 min after administration. Clonidine, 300 ~tg/kg, i.v., caused a significant and dose-dependent 
decrease in CSF 5-HIAA from either basal levels or those measured in saline-treated animals at the same point in 
time (Table II). 
CSF DOPAC concentrations: Basal levels of  CSF DOPAC in clonidine-administered groups did not significantly 
differ from those of saline treated control rats. The CSF DOPAC concentrations were not significantly changed 60 
rain and 120rain after saline administration. Clonidine (3, 30 and 300 ~g/kg, i.v.) decreased the CSF DOPAC 
concentrations in a dose-dependent manner (Table III). 
Idazoxan pretreatment: In order to confirm the involvement of c~2_adrenoceptors in the clonidine-induced decreases 
o fCSF  5-HT and 5-HIAA concentrations, a specific ~2-adrenoceptor antagonist, idazoxan, was used. Basal levels 
of  CSF 5-HT and 5-HIAA in idazoxan treated rats did not differ from those of either saline- or clonidine- 
administered rats. Idazoxan (5 mg/kg, i.p) by itself did not significantly alter CSF 5-HT and 5-HIAA 
concentrations. Pretreatment with idazoxan (5 mg/kg, i.p.) attenuated the decreased CSF 5-HT and 5-HIAA 
concentrations 60 rain and 120 rain after i.v. administration of clonidine (30 lag/kg)(Table I and II). Clonidine (30 
~tg/kg, i.v.)-induced decreases in CSF DOPAC concentrations were also abolished significantly by pretreatment 
with idazoxan (Table III). 
6-OHDA pretreatment: In rats pretreated with 6-OHDA, basal levels of  both CSF 5-HT and 5-HIAA did not 
significantly differ from those of non-lesioned normal rats. CSF DOPAC concentrations in 6-OHDA pretreated 
rats were 5.30 + 1.02 ng/ml, which represented a significant 70% reduction compared with the levels in non- 
lesioned rats (<0.001). In 6-OHDA pretreated rats, clonidine (30 pg/kg,  i.v) failed to decrease CSF 5-HT 
concentrations 60 min and 120 min after administration (Table I). Clonidine-induced decreases in CSF 5-HIAA 
levels were also significantly inhibited by 6-OHDA pretreatment (Table II). 
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T A B L E  II 
E f f e c t s  o f  C l o n i d i n e  on  C e r e b r o s p i n a l  F l u i d  (CSF)  5 - H I A A  C o n c e n t r a t i o n s  ( n g / m l ) .  
G r o u p s  (n) 0min  6 0 m i n  %Chan~e 1 2 0 m i n  
C o n t r o l  (7)  199 .89  2 1 6 . 6 7  7 .92  1 9 6 . 9 4  
_+19.14 _+26.72 ±9.37 _+21.82 
C l o n i d i n e  (4) 177 .88  157 .91  - 3 . 4 7  1 9 0 . 4 4  
(3 gg~g, i.v.) ±20 .74  ±22 .43  ±1.96 ±36 .64  
C l o n i d i n e  (5) 175 .63  1 3 4 . 1 9  - 2 3 . 1 2 "  129 .91  
(30 p.g/kg, i.v.) ±21 .15  ±16 .19  ±4.31 ±14 .43  
C l o n i d i n e  (6) 183 .97  121 .19  -34.08** 1 0 9 . 3 0  
(300 rtg/kg, i.v.) ±12 .15  ±17 .20  _+8.32 _+23.44 
I d a z o x a n  (5) 1 7 0 . 0 2  181 .67  1 0 . 1 2  1 7 7 . 2 0  
(5 mg/kg, i.p.) ±21 .13  ±18 .77  ±10 .47  ±20 .92  
l d a z o x a n ( 5  mg/kg,i.p.) (5) 1 4 7 . 2 6  1 6 3 . 3 7  12 .38##  1 6 6 . 2 6  
+ C l o n i d i n e  ±17 .92  ±19 .52  ±8.12 ±16.81  
(30 ~tg/kg, i.v.) 
6 -OHDA(200  p.g,i.c.v.) (5) 1 4 3 . 8 3  1 4 0 . 1 5  - 1 . 3 3 #  1 1 1 . 0 0  
+ C l o n i d i n e  _+14.62 ±13 .85  _+7.12 ±10 .22  
(30 ~.~/k~, i.v.) 
Data presented are mean ± SEM. * p<0.05 and ** p<0.01 compared to controls. 
# p<0.05 and ## p<0.01 compared to clonidine (30 ~ag/kg, i.v.) treated rats. 
%Chan~e 
- 1 . 1 6  
±6.27 






7 .20  
±10 .48  
16 .32##  
±10 .76  
- 2 2 . 2 1  
±11 .01  
T A B L E  II1 
E f f e c t s  o f  C l o n i d i n e  on  C e r e b r o s p i n a l  F lu id  (CSF)  D O P A C  C o n c e n t r a t i o n s  (ng /ml ) .  
G r o u p s  (n) 0min  6 0 m i n  %Chan~e 1 2 0 m i n  %Chan~e 
C o n t r o l  (6) 1 7 . 8 8  1 9 . 2 9  1 4 . 9 3  1 7 . 5 4  5 .92  
±2.54 ±2.88 ±18 .44  ±2.30 ±9.93 
C l o n i d i n e  (4)  15 .01  14 .17  - 8 . 1 3  12 .61  - 1 4 . 1 7  
(3gg&g,i .v.)  ±2.45 ±2.82 _+4.06 _+1.71 ±4.88 
C l o n i d i n e  (5) 1 8 . 8 3  1 0 . 6 3  -38 .39*  9 .52  -43 .16"*  
(30 ~g~g,i .v.)  ±3.77 ±1.37 ±9.28 ±0.96 ±9.57 
C l o n i d i n e  (6)  2 3 . 4 1  1 1 . 2 9  -46.09** 1 1 .4 1  -48,60** 
(300 p.g/kg, i.v.) ±3.79 ±1.64 ±10 .17  ±3.00 ±8.32 
I d a z o x a n  (4) 18 .47  1 8 . 9 0  0 .43  1 7 . 1 2  - 1 . 3 5  
(5 mg/kg, i.p.) _+1.96 ±3.54 ±12 .17  ±2.60 ±12 .08  
I d a z o x a n ( 5  mg/kg,i.p.) (5) 1 6 . 3 4  1 7 . 1 2  7 . 5 0 # #  1 7 . 6 5  
+ C l o n i d i n e  ±1.43 ±0.68 _+8.72 _+1.68 
(30 p.~,'k$, i.v.) 
Data presented are mean ± SEM. * p<0.05 and ** p<0.01 compared to controls. 
# p<0.05 and ## p<0.01 compared to clonidine (30 p.g/kg, i.v.) treated rats. 
1 1 . 6 7 #  
±14 .00  
D i s c u s s i o n  
The present  s tudy revealed that c lonidine p roduced  dose-dependent  decreases  in C S F  5-HT concentra t ions  in 
anes the t ized  rats.  C S F  5 - H I A A  concen t r a t i ons  a lso  dec reased  af ter  c lon id inc  adminis t ra t ion .  C lon id ine - induced  
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decreases in CSF 5-HT and 5-HIAA concentrations were attenuated by pretreatment with idazoxan. Idazoxan by 
itself did not alter either CSF 5-HT or 5-HIAA levels. These results suggest the possibility that clonidine acts to 
inhibit the central serotonergic neuronal activity via the ct2-adrenoceptors. Furthermore, it indicates that the 
serotonergic neuronal activity is not tonically influenced by ¢t2-adrenoceptors. The clonidine-induced decreases in 
both CSF 5-HT and 5-HIAA concentrations were abolished by noradrenergic denervation caused by pretreatment of 
6-OHDA. Thus, the noradrenergic nervous system might be involved in the inhibitory effect of  clonidine on 
serotonergic neuronal activity. In this experiment, clonidne decreased CSF DOPAC concentrations dose- 
dependently and these effects were significantly abolished by the pretreatment with idazoxan. Our findings were in 
agreement with reports by Tibirica et al. (18) who showed, using in vivo voltammetry, that the DOPAC oxidation 
peak in both locus coeruleus and nucleus reticularis lateralis was decreased by clonidine. Their electrophysiological 
studies have shown that a correlation between the amplitude of the DOPAC peak and the firing rate of the 
noradrenergic neurons, i.e., the DOPAC peak can be used as an index of the functional activity of noradrenergic 
neurons. Our previous data also indicated that CSF DOPAC concentrations reflect the central noradrenergic 
neuronal activity, since CSF DOPAC concentrations correlated positively with brain NA contents in rats 
(unpublished data). The present fact that clonidine-induced decreases in CSF DOPAC concentrations were inhibited 
by pretreatment with idazoxan confirmed, therefore, that clonidine acts to inhibit noradrenergic neurons via the ot2- 
adrenoceptors. Taken together, they support the possibility that noradrenergic nervous systems may be involved in 
the inhibitory effects of clonidine on serotonergic neuronal activity. 
There are many speculations about the mechanism of the inhibitory effects of clonidine on serotonergic 
neuronal activity, i.e., clonidine produced decreases in both 5-HT and 5-HIAA concentrations in the CSF. One 
possibility is that clonidine modulates the biosynthesis, not the metabolism, of 5-HT neurons. This hypothesis is 
supported by the report that systemic administration of clonidine decreased 5-HTP accumulation in the rat cerebral 
cortex (8). We have also observed that 5-HTP accumulation in the rat dorsal raphe nucleus and hippocampus were 
decreased by clonidine (19). Another possibility is that clonidine suppresses the 5-HT release from the nerve 
terminals. Some in vitro studies have demonstrated the presence of ct2-adrenoceptors on serotonergic nerve 
terminals in the rat brain (20, 21). Recently we have showed that the physiological modulation of clonidine on 5- 
HT release via the ot2-adrenoceptors, which are located on the scrotonergic nerve terminals, exists in the rat 
hippocampus (22). Although more detailed studies are needed with regard to these mechanisms, the CSF 5-HT and 
5-HIAA concentrations certainly could reflect the global neuronal activity including biosynthesis and/or release of 
5-HT. 
The source of CSF 5-HT has been unclear. Anatomical and histochemical evidence have revealed the 
distribution of serotonergic neurons : the choroid plexus, the major site of CSF production, which is innervated 
by serotonergic and noradrenergic nerves (23). The brainstem, including the raphe nucleus which contains the 
highest density of  5-HT cell bodies, is adjacent to the third ventricle. The dorsal raphe nucleus receives direct 
projections of noradrenergic nerve terminals from the locus coeruleus (1). Furthermore, the ventromedial raphe 
magnus contains a high density of ot2-adrenoceptors as well as 5-HT neuronal cell bodies (24). Our previous study 
that clonidine-induced decreases of the 5-HTP accumulation in the dorsal raphe nucleus were abolished by 6-OHDA 
pretreatment (19) suggested that noradrenergic neurons are involved in the inhibitory action of clonidine on 5-HT 
biosynthesis in the dorsal raphe nucleus. Geyer and Lee (9) reported that clonidine suppressed the 5-HT neuronal 
firing in the dorsal raphe nucleus which was mediated through the noradrcnergic neurons. These results are in 
agreement with the present data showing that clonidine-induced decreases in CSF 5-HT levels were prevented by 
noradrenergic destruction. Therefore, the CSF 5-HT levels may partially reflect the serotonergic neuronal activity 
in the dorsal raphe nucleus. 
More recent studies have pointed out that extracellul~ 5-HIAA levels do not reflect the serotonergic 
neuronal activity. These studies showed that the extracellular 5-HIAA levels during potassium(K+)-stimulation 
(25) or experimental ischemia (26) did not change in parallel with the 5-HT release. In our experiment using in 
vivo microdialysis, extracellular 5-HIAA levels were not affected by K+-stimulation despite increases in 5-HT 
levels (22). De Simoni et al. (27) have shown that the caudate 5-HIAA levels did not increase following 
administration of tryptophan (Trp), even though brain 5-HIAA contents increased. In contrast, some investigators 
reported that the extracellular 5-HIAA levels in the striatum (28) and the CSF 5-HIAA levels rose after Trp 
administration (29). We also observed that systemic administration of 5-HTP (50 and 150 mg/kg, i.p.) caused 
increases in CSF 5-HIAA levels in parallel with increases in CSF 5-HT levels (30). Moreover, 5-HT neurotoxin, 
5,7-dihydroxytryptamine, decreased not only CSF 5-HT but also CSF 5-HIAA concentrations (16). Thus, the 
CSF 5-HIAA concentrations changed simultaneously with the CSF 5-HT levels. These results strengthen the 
premise that the 5-HIAA levels in the CSF provide a reliable index of central serotonergic nerve activity. 
In summary, the present study suggests that clonidine acts to inhibit the serotonergic neuronal activity, 
which is partially mediated via the et2-adrenoceptors. It indicates, moreover, the possibility that noradrenergic 
nervous systems are involved in the clonidine-induced inhibition of serotonergic neuronal activity. In other words, 
the physiological and functional interactions between serotonergic and noradrenergic nervous systems exist in vivo, 
i.e., the activity of serotonergic neurons might be modulated by noradrenergic neurons. The present study also 
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demonstrates that the determination of CSF 5-HT and 5-HIAA concentrations in anesthetized rats is a useful and 
significant method for studying the pharmacological effects on the central serotonergic neuronal activity including 
biosynthesis, metabolism and/or release. 
R e f e r e n c e s  
1. J.M. BARABAN and G.K. AGHAJANIAN, Brain Res. 204 1-11 (1981). 
2. V.M. PICKEL, T.H. JOH and D. REIS, Brain Res . /3 /  197-214 (1977). 
3. S.L. FOOTE, E.B. FLOYD and G. ASTON-JONES, Physiol. Rev. 63 844-914 (1983). 
4. J.M. CEDARBAUM and G.K. ACHAJANIAN, Eur. J. Pharmacol. 44 375-385 (1977). 
5. S.Z. LANGER, Pharmacol. Rev. 32 337-362 (1981). 
6. K. STARKE, Rev. Physiol. Biochem. Pharmacol. 77 1-124 (1977). 
7. T.C. Westfall, Physiol. Rev. 57 659-728 (1977). 
8. J.F. REINHARD JR and R.H. ROBERT, J. Pharmacol. Exp. Ther. 22/ 541-546 (1982). 
9. M.A. GEYER and E.H.Y. LEE, Biochem. PharmacoL 33 3399-3404 (1984). 
10. J. MAJ, L. BARAN, M. GRABOWSKA and H. SOWINSKA, Biochem Pharmacol. 22 2679-2683 (1973). 
11. H-W. CLEMENT, D. GEMSA and W. WESEMANN, Eur. J. Pharamacol. 2/7 43-48 (1992). 
12. L.X. GUBEDDU, I.S. HOFFMANN, J. DAVILA, Y.R. BARBELLA and P. ORDAZ, Life Sci. 35 1365- 
1371 (1984). 
13. I.N. MEFFORD and N.A. GARRICK, Brain Res. 492 377-380 (1989). 
14. G.M. ANDERSON, I.N. MEFFORD, T.J. TOLLIVER, M.A. RIDDLE, D.M. OCAME, J.F. LECKMAN 
and D.J. COHEN. Life. Sci. 46 247-255 (1990). 
15. M. MATSUMOTO, H. TOGASHI, M. YOSHIOKA, M. HIROKAMI, K. MORII and H. SAITO, J. 
Chromatogr. 52____66 1-10 (1990). 
16. M. MATSUMOTO, H. TOGASHI, M. YOSHIOKA, K. MORII, M. HIROKAMI, M. TOCHIHARA, T. 
IKEDA, Y. SAITO and H. SAITO, Life Sci. 48 823-829 (1991). 
17. L. QUINTIN, G. HILAIRE and J.F. PUJOL, Neuroscience L8 889-899 (1986). 
18. E. TIBIRICA, C. MERMET, J. FELDMAN, F. GONON and P. BOUSQUET, J. Pharmacol. Exp. Ther. 
250 642-647 (1989). 
19. M. YOSHIOKA, M. MATSUMOTO, H. TOGASHI, C.B. SMITH and H. SA1TO. Neuroscience Lett./39 
53-56 (1992). 
20. A.L. FRANKHUYZEN and A.H. MULDER, Eur. J. Pharmacol. 63 179-182 (1980). 
21. G. MAURA, A. GEMIGNANI and M. RAITERI, Naunyn-Schmiedeberg's Arch Pharmacol. 334 323-326 
(1982). 
22. M. YOSHIOKA, M. MATSUMOTO, H. TOGASHI, C.B. SMITH and H. SAITO, Neuroscience Lett. /39 
57-60 (1992). 
23. M. LINDVALL, L. EDVINSSON and C. OWMAN, Science 201 176-178 (1978). 
24. J.R. UNNERSTALL, T.A. KOPAJTIC and M.J. KUHAR, Brain Res. 7 69-101 (1984). 
25. P. KALEN, R.E. STRECKER, E. ROSENGREN and A. BJORKLUND, J. Neurochem. 5____L 1422-1435 
(1988). 
26. G.S. SARNA, T.P. OBRENOVITCH, T. MATSUMOTO, L. SYMON and G. CURZON, J. Cereb. Blood 
Flow Metab. 9 S184 (1989). 
27. M.G. DE SIMONI, A. SOKOLA, F. FODRITTO, G. DAL TOSO and S. ALGERI, Brain Res. 41._.1_1 89-94 
(1987). 
28. G.S. SARNA, P.H. HUTSON, M.T. O'CONNELL and G. CURZON, J. Neurochem. 56 1564-1568 (1991). 
29. P.H. HUTSON, G.S. SARNA, B.D. KANTAMANENE and G. CURZON, J. Neurochem. 4._4_4 1266-1273 
(1985). 
30. H. TOGASHI, M. MATSUMOTO, M. YOSHIOKA, M. MINAMI and H. SAITO. Biogenic amines ~. 15-27 
(1992). 
